DeepCyte, a techbio company focused on AI-driven toxicology for drug development, announced its launch alongside $1.5 million in seed funding to advance its single-cell analysis platform and predictive AI tools.
The company aims to address one of the most persistent challenges in drug development, toxicity, which remains a leading cause of clinical trial failure and post-market drug withdrawals. Traditional approaches such as animal testing and bulk assays often fail to accurately predict human responses or capture the complexity of cellular-level effects.
DeepCyte is introducing two core solutions designed to improve how toxicity is detected, predicted, and understood. Its MetaCore platform is a high-throughput single-cell metabolomics system that uses laser-based sampling and mass spectrometry to generate detailed molecular profiles of individual cells. This enables researchers to observe heterogeneous cellular responses that conventional methods typically miss.
Building on this data, DeepCyte has developed DeeImmuno, an AI-powered toxicology platform trained on proprietary single-cell metabolomics datasets. The system is designed to predict toxicity classes, identify biomarkers, and explain the underlying molecular mechanisms of adverse effects. In internal evaluations across 100 drugs, DeeImmuno achieved 94 percent accuracy in predicting 17 distinct toxicity mechanisms.
The company’s approach aligns with increasing regulatory emphasis on human-relevant and mechanism-based testing, as agencies such as the FDA and EMA push for alternatives to traditional preclinical models.
DeepCyte is headquartered in Wilmington, Delaware, and Copenhagen, Denmark, and is led by a team with experience across pharmacology, artificial intelligence, and life sciences commercialization.
KEY QUOTE:
“DeepCyte’s mission is to reveal and prevent toxicity in every cell, at scale, before drugs reach patients. By combining advances in AI and single-cell biology, we predict not only whether a drug is toxic, but also why.”
Theodore Alexandrov, Ph.D., CEO and Co-Founder, DeepCyte
